The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://geraldrrfv431368.csublogs.com/46613717/glp-3-retatrutide-a-comparative-analysis